How much funding has SpyGlass Pharma raised?

SpyGlass Pharma has raised $199.2M in total funding, most recently a Series D round.

Who are SpyGlass Pharma's investors?

SpyGlass Pharma's investors include RA Capital Management, Sands Capital, Gilde Healthcare, New Enterprise Associates.

When was SpyGlass Pharma founded?

SpyGlass Pharma was founded in 2019.

Where is SpyGlass Pharma headquartered?

SpyGlass Pharma is headquartered in Aliso Viejo, California, United States.

What industry is SpyGlass Pharma in?

SpyGlass Pharma operates in Biotech, Healthcare.

How many employees does SpyGlass Pharma have?

SpyGlass Pharma has 51-200 employees.

SpyGlass Pharma

IPO

Sustained Drug Delivery

Public · Aliso Viejo, United States · Founded 2019 · $199.2M raised

Biotech

Healthcare

Headquarters: Aliso Viejo, California
Employees: 51–200
Founded: 2019
Business Model: B2B
Website: spyglasspharma.com

Total Funding: $199.2M
Last Round: $75.0M Series DJun 2025
Rounds: 5
Type: Public

About

SpyGlass Pharma is a late-stage biopharmaceutical company developing implantable ophthalmic drug delivery systems for patients with glaucoma and ocular hypertension. Its BIM-IOL System delivers sustained-release bimatoprost from an intraocular lens implanted during routine cataract surgery, aiming to eliminate lifelong eye drop dependence. The company went public on Nasdaq (SGP) in February 2026.

Summary

SpyGlass Pharma is a Biotech company based in Aliso Viejo, United States, founded in 2019. It has raised $199.2M in total across 5 rounds, most recently a $75.0M Series D round in Jun 2025. Investors include RA Capital Management, Sands Capital and Gilde Healthcare.